Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline Review, H2 2016’, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease

The report reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutics and enlists all their major and minor projects

The report assesses Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AstraZeneca Plc

Bristol-Myers Squibb Company

Complexa Inc

Dilaforette AB

Gilead Sciences Inc

Novartis AG

NuvOx Pharma LLC

Pfizer Inc

Seattle Genetics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Overview 7

Therapeutics Development 8

Pipeline Products for Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview 8

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics under Development by Companies 9

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Products under Development by Companies 13

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Companies Involved in Therapeutics Development 14

AstraZeneca Plc 14

Bristol-Myers Squibb Company 15

Complexa Inc 16

Dilaforette AB 17

Gilead Sciences Inc 18

Novartis AG 19

NuvOx Pharma LLC 20

Pfizer Inc 21

Seattle Genetics Inc 22

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

apixaban - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CXA-10 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

NVX-508 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

regadenoson - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

rivipansel sodium - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

SelG-1 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

sevuparin sodium - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

SGD-2083 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

ticagrelor - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects 61

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products 62

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Product Development Milestones 63

Featured News & Press Releases 63

Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel 63

Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology 63

Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel 64

Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015 65

Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting 65

Sep 26, 2014: GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel 65

Jul 01, 2014: GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070) 66

May 21, 2014: GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial 66

Sep 13, 2013: GlycoMimetics Announces EMA’s Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease 67

Aug 19, 2013: Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises 67

Jan 17, 2013: GlycoMimetics Completes Enrollment In Phase II Sickle Cell Disease Study With Lead Drug Candidate GMI-1070 68

Dec 11, 2012: Glycomimetics Presents Data From Pilot Study Of GMI-1070 At ASH Annual Meeting 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

List of Tables

Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by AstraZeneca Plc, H2 2016 14

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Bristol-Myers Squibb Company, H2 2016 15

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Complexa Inc, H2 2016 16

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Dilaforette AB, H2 2016 17

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Gilead Sciences Inc, H2 2016 18

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Novartis AG, H2 2016 19

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by NuvOx Pharma LLC, H2 2016 20

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Pfizer Inc, H2 2016 21

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Seattle Genetics Inc, H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Stage and Target, H2 2016 25

Number of Products by Stage and Mechanism of Action, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Dormant Projects, H2 2016 61

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Discontinued Products, H2 2016 62

List of Figures

List of Figures

Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Targets, H2 2016 24

Number of Products by Stage and Targets, H2 2016 24

Number of Products by Mechanism of Actions, H2 2016 26

Number of Products by Stage and Mechanism of Actions, H2 2016 26

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Types, H2 2016 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports